Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit”

Group 1 - Eli Lilly and Company (NYSE: LLY) is highly regarded by analysts, with a strong recommendation to hold and potentially buy more shares if the stock price declines [1][3] - The company is a leading developer of GLP-1 medications, which have shown significant promise beyond weight loss and diabetes treatment, including potential applications for alcohol and tobacco addiction [3] - Eli Lilly's market position is strengthened by its joint venture with NVIDIA, focusing on developing treatments for hard-to-treat diseases, which could lead to long-term growth opportunities [3] Group 2 - Eli Lilly's success is impacting its main competitor, Novo Nordisk, as it continues to capture market share [3] - While Eli Lilly is recognized for its potential, some analysts suggest that certain AI stocks may offer greater upside potential with less risk [4]